

## Demographic, Clinical, and Angiographic Characteristics of Atrial Fibrillation Patients Suffering from de Novo Acute Myocardial Infarction: A Subgroup Analysis of the MINOCA-TR Study Population

Ali Coner<sup>1</sup>, Cenk Ekmekci<sup>2</sup>, Gokhan Aydin<sup>3</sup>, Yasemin Kilavuz Dogan<sup>4</sup>, Ozlem Arican Ozluk<sup>5</sup>, Salih Kilic<sup>6</sup>, Yunus Celik<sup>7</sup>, Ismail Ungan<sup>8</sup>, Mustafa Begenc Tascanov<sup>9</sup>, Ramazan Duz<sup>10</sup>, Veli Polat<sup>11</sup>, Hakan Ozkan<sup>12</sup>, Mehmet Ozyasar<sup>13</sup>, Kamil Tuluce<sup>14</sup>, Abdullah Icli<sup>15</sup>, Devrim Kurt<sup>16</sup>, Nurullah Cetin<sup>14</sup>, Murat Gul<sup>17</sup>, Sinan Inci<sup>18</sup>, Mehdi Zoghi<sup>19</sup>, Oktay Ergene<sup>20</sup>, Ugur Onsel Turk<sup>21</sup>

<sup>1</sup>Baskent University Hospital Alanya Application and Research Center, Antalya, Turkey.

<sup>2</sup>Tepecik Training and Research Hospital, Izmir, Turkey.

<sup>3</sup>Health Sciences University, Balikesir Training and Research Hospital, Balikesir, Turkey.

<sup>4</sup>Health Sciences University, Kayseri Training and Research Hospital, Kayseri, Turkey.

<sup>5</sup>Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.

<sup>6</sup>Health Sciences University, Adana Training and Research Hospital, Adana, Turkey.

<sup>7</sup>Kirikkale Yuksek Ihtisas Hospital, Kirikkale, Turkey.

<sup>8</sup>Yalova State Hospital, Yalova, Turkey.

<sup>9</sup>Tokat Medical Park Hospital, Tokat, Turkey.

<sup>10</sup>Health Sciences University, Van Training and Research Hospital, Van, Turkey.

<sup>11</sup>Bakirkoy Doctor Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

<sup>12</sup>Bursa Medical Park Hospital, Bursa, Turkey.

<sup>13</sup>Karaman State Hospital, Karaman, Turkey.

<sup>14</sup>Cigli Regional Training and Research Hospital, Izmir, Turkey.

<sup>15</sup>Necmettin Erbakan University Faculty of Medicine, Konya, Turkey.

<sup>16</sup>Giresun University Prof. Dr. A. Ilhan Ozdemir Training and Research Hospital, Giresun, Turkey.

<sup>17</sup>Aksaray University Training and Research Hospital, Aksaray, Turkey.

<sup>18</sup>Aksaray State Hospital, Aksaray, Turkey.

<sup>19</sup>Ege University Faculty of Medicine, Izmir, Turkey.

<sup>20</sup>Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.

<sup>21</sup>KardiyoRitm Heart Center, Izmir, Turkey.

### Abstract

**Background:** Atrial fibrillation (AF) prevalence in patients with acute myocardial infarction (MI) ranges from 3% to 25%. However demographic, clinical, and angiographic characteristics of AF patients who admitted with de novo MI are unclear. The aim of this study was to investigate the prevalence of patients presenting with de novo MI with AF.

**Methods:** The study was performed as a sub-study of the MINOCA-TR (Myocardial Infarction with Non-obstructive Coronary Arteries in Turkish Population) Registry, a multicenter, cross-sectional, observational, all-comer registry. MI patients without a known history of stable coronary artery disease and/or prior coronary revascularization were enrolled in the study. Patients were divided into AF and Non-AF groups according to presenting cardiac rhythm.

**Results:** A total of 1793 patients were screened and 1626 were included in the study. The mean age was 61.5 (12.5) years. 70.7% of patients were men. The prevalence of AF was 3.1% (51 patients). AF patients were older [73.4 (9.4) vs. 61.0 (12.4) years,  $p < 0.001$ ] than non-AF patients. The proportion of women to men in the AF group was also higher than in the non-AF group (43.1% vs. 28.7%,  $p = 0.027$ ). Only 1 out of every 5 AF patients (10 patients, 19.6%) was using oral anticoagulants (OAC).

**Conclusions:** AF prevalence in patients presenting with de novo MI was lower than previous studies that issued on AF prevalence in MI cohorts. The majority of AF patients did not have any knowledge of their arrhythmia and were not undergoing OAC therapy at admission, emphasizing the vital role of successful diagnostic strategies, patient education, and implementations for guideline adaptation.

## Key Words

Atrial fibrillation, Myocardial infarction, Oral anticoagulation, MINOCA-TR study.

## Corresponding Author

Ali Coner, MD, Cardiologist Postal address: Baskent University Hospital Alanya Application and Research Center, Saray district, Yunus Emre Street, Number: 1, zip code: 07400, Alanya/Antalya, Turkey

## Introduction

Atrial fibrillation (AF) is a common arrhythmia in the general population and ranks third in incidence in patients with myocardial infarction (MI) after sinus bradycardia and sinus tachycardia<sup>1</sup>. Previous studies have reported a wide variety in the prevalence rates of AF in the MI population<sup>2,3</sup>. European Society of Cardiology (ESC) 2017 Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation (STEMI) reported prevalence rates as high as 21% for MI patients<sup>4</sup>. AF can result in undesired in-hospital outcomes<sup>5</sup> such as recurrent coronary ischemia, congestive heart failure, or stroke, as well as the need for long-term oral anticoagulation use, which increases rates of bleeding complications<sup>6</sup>. Preexisting, known coronary artery disease (CAD) is a well-recognized comorbidity in patients with AF. CAD and other comorbidities carry the risk for incident AF. Interestingly, there is scarce demographic and clinical information in the literature on AF in the MI population without a history of CAD and coronary revascularization. Evidence for acute management and long-term treatment strategies such as oral anticoagulation are not clear and should be identified<sup>7</sup>.

This study aimed to determine prevalence rates of AF in de novo MI patients without revascularization history and to compare the demographic, clinical, and angiographic characteristics of patients with and without AF in the de novo MI population in Turkey.

## Methods

### Study design

The registry of Myocardial Infarction with Non-obstructive Coronary Arteries in the Turkish population (MINOCA-TR) is a nationwide, multicenter, prospective, and observational cohort study of patients with a de novo myocardial infarction (MI) presentation. A total of 32 invasive cardiology centers (eighteen university, ten state, and four private hospitals) around Turkey participated to the study. Patient recruitment was performed between March to October 2018. Patients without a known history of prior coronary revascularization who underwent a diagnostic coronary angiography procedure with a possible diagnosis of MI were screened and included in the study population. The aim of this screening was to obtain real-life data and prevent potential bias in the clinical context. A sub-study of the MINOCA-TR registry, this paper focuses on the prevalence of AF in the MINOCA-TR study population<sup>8,9</sup>. The study population was divided into two groups, the AF and non-AF groups, based on their presenting rhythm at admission. Demographic, clinical, and angiographical data of the MINOCA-TR study population was recorded and compared. The study protocol of the MINOCA-TR was approved by the Clinical Research Ethical Committee of Dokuz Eylul University and was registered with [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT03364387).

## Study population

Consecutive patients 18 years of age and older who were diagnosed with MI using the Third Universal Definition of Myocardial Infarction and who underwent a diagnostic coronary angiography were included in the study population. Each participating physician arranged the management of treatment on their own, and the study patients were not given any medical procedure other than guideline directed therapy. Potential study patients were informed about the study and asked to sign informed consent forms after coronary angiography (or percutaneous coronary interventions if needed). Patients with stable coronary artery disease, unstable angina pectoris, coronary revascularization history (PCI or CABG), or type 4 or type 5 MI and patients under the years of 18 and who did not sign the informed consent were excluded from the study.

## Coronary angiographies

Coronary angiographies were performed in the individual centers involved in the study. A digital copy of each recording was sent to the MINOCA-TR adjudication committee, which was made up of three invasive cardiologists. Coronary angiographies were evaluated for the possible presence of an overlooked type 1 MI.

## Statistical Analysis

Statistical analysis was descriptive, exploratory, and generally limited to frequency or summary statistics (e.g., means  $\pm$  standard deviation or medians  $\pm$  quartiles). Demographic information was summarized according to the type of data by descriptive statistics (n, mean, standard deviation, median, the difference between percentiles) or frequency

**Table 1: Demographic and clinical characteristics of study population at admission**

	AF patients(n=51)	non-AF patients(n=1575)	p value
Mean age (years), mean (SD)	73.4 (9.4)	61.0 (12.4)	<0.001
Female gender, n (%)	22 (43.1)	453 (28.7)	0.027
BMI (kg/m <sup>2</sup> ), mean (SD)	26.9 (4.1)	27.6 (4.4)	0.522
Smoking, n (%)	20 (39.2)	922 (58.6)	0.006
Diabetes mellitus, n (%)	20 (39.2)	460 (30.3)	0.174
Hypertension, n (%)	33 (64.7)	744 (48.5)	0.023
Hyperlipidemia, n (%)	15 (32.6)	482 (35.9)	0.640
Systolic blood pressure (mmHg), mean (SD)	130.9 (27.3)	128.9 (23.3)	0.872
Diastolic blood pressure (mmHg), mean (SD)	78.2 (16.2)	77.3 (13.9)	0.761
Admission Killip class ( $\geq$ 3), n (%)	2 (3.9)	47 (2.9)	0.001
LV ejection fraction (%), median (25th-75th percentile)	45.0(30.0-50.0)	50.0(35.0-55.0)	0.008
Presence of severe ( $\geq$ 3rd degree) MR, n (%)	6 (11.7)	27 (1.7)	<0.001
Blood glucose (mg/dL), median (25th-75th percentile)	140.0(85.0-192.0)	123.0(81.0-176.0)	0.086
Creatinine (mg/dL), median (25th-75th percentile)	0.90(0.71-1.50)	0.85(0.67-1.31)	0.203
Hemoglobin (gr/dL), mean (SD)	12.7 (2.2)	13.6 (1.9)	0.004
hs-Troponin (ng/mL), median (25th-75th percentile)	15.2(1.4-97.1)	15.3(0.9-428.0)	0.689
NSTEMI presentation, n (%)	35 (68.6)	839 (53.2)	0.023

Abbreviations: BMI, body mass index; LV, left ventricle; MR, mitral regurgitation

**Table 2: Percentages of oral P2Y<sub>12</sub> loading at admission and preexisting use of oral anticoagulant**

	AF patients(n=51)	non-AF patients(n=1575)	p value
P2Y <sub>12</sub> inhibitors loading, n (%)	49 (96.0%)	1446 (91.8%)	0.027
Preexisting oral anticoagulant use, n (%)	10 (19.6%)	16 (1.0%)	<0.001

distribution (n and %). The Student's t-test was used for continuous variables, the analysis of variance for categorical variables, and the Pearson's chi-square test for binominal variables. P values of <0.05 were accepted as significant.

## Results

### Baseline characteristics of study population

A total of 1793 patients were screened for eligibility. Of these, 1626 patients admitted with de novo acute MI were enrolled in this study. The mean (SD) age of the population was 61.5 (12.5) years and men made up 70.7% of the study population. Fifty-one (3.1%) patients were diagnosed with AF. Dramatically, the minority of patients were previously diagnosed with AF (14 patients, 27.4%) and only 1 out of every 5 AF patients (10 patients, 19.6%) was using oral anticoagulants (OAC). Demographic and clinical characteristics of the study population are presented in [Table 1]. Patients in the AF group were older than the non-AF group [mean 73.4 (9.4) vs. 61.0 (12.4) years,  $p<0.001$ ]. The percentage of women in the AF group was also higher than that in the non-AF group (43.1% vs. 28.7%,  $p=0.027$ ). Non-ST segment elevation MI (NSTEMI) presentation (68.6% vs. 53.2%,  $p=0.023$ ) and prevalence of hypertension (64.7% vs. 48.5%,  $p=0.023$ ) were more common in patients in the AF group. Conversely, fewer patients in the AF group smoked than in the non-AF group (39.2% vs. 58.6%,  $p=0.006$ ). Median LV ejection fraction at admission was lower in AF patients than the non-AF patients [45.0% (30–50%) vs. 50.0% (35–55%),  $p=0.008$ ]. Hemoglobin levels were also lower in the AF group [12.7 (2.2) vs. 13.7 (1.9) gr/dL,  $p=0.004$ ]. A greater number of patients in the AF group were classified as Killip class 3 and 4 at admission (3.9% vs. 2.9%,  $p=0.001$ ). Severe mitral regurgitation was more common in AF patients (11.7% vs. 1.7%,  $p<0.001$ ). Although the STEMI rate was 46.0% for the entire study population, only 3.0% of the total population, none of which were in the AF group, received thrombolytic treatment as a reperfusion therapy before diagnostic coronary angiography. Oral P2Y<sub>12</sub> inhibitor loading before the index emergency admission rate was higher in AF patients (96.0% vs. 91.8%,  $p=0.027$ ). Clopidogrel was the most commonly used P2Y<sub>12</sub> inhibitor in the study population (49.2%). On the other hand, the loading rate of oral P2Y<sub>12</sub> inhibitors other than clopidogrel was 31.3% in the AF and 47.6% in the non-AF group ( $p=0.004$ ). Preexisting oral anticoagulant use was also higher in AF patients (19.6% vs. 1.0%,  $p<0.001$ ) [Table 2].

### Coronary angiography results

The majority of patients were treated via primary percutaneous intervention (1280 patients, 78.7% of the overall study population). Coronary artery bypass grafting was the preferred method for revascularization for 10.5% of cases and medical management was preferred for 10.2%. The selected treatment options were similar between the AF and non-AF patients [Table 3]. The percentages of patients diagnosed with MINOCA were also similar between groups (7.8% vs. 6.6%,  $p=0.743$ ).

## Discussion

In the current study investigating the prevalence and demographic and clinical characteristics of AF in patients with de novo myocardial infarction, we found a lower prevalence rate of 3.1%, in contrast to previous studies in the literature<sup>2,3,10,11</sup>. Similar to our results, the HORIZONS-AMI study reported a low AF incidence (4.5%) in patients undergoing primary percutaneous coronary intervention (pPCI). Mean age in AF and non-AF groups were also similar to our study. Relatively low percentage of patients with a previous history of percutaneous or surgical revascularization (approximately 13%) in the HORIZONS-AMI study population might be the factor in low new-onset AF development<sup>12</sup>. The exclusion of patients with a previous history of revascularization and diagnosis of stable coronary artery disease (stable CAD) as well as the relatively younger age of the enrolled population is thought to play a main role in the lower than expected prevalence of AF in our study. Stable CAD and AF share common risk factors and patients with a long history of stable CAD and its risk factors also show increased risk of incident AF<sup>13</sup>. In addition, coronary revascularization procedures, particularly CABG, have been found to create a predisposition to incident AF<sup>14</sup>. For this reason, the authors are of the opinion that the exclusion of patients with stable CAD and revascularization history were the main factors behind the low percentage of AF patients in the study population. Furthermore, a positive correlation between age and AF has been confirmed in many registries<sup>15,16</sup>. The relatively young mean age (approximately 60 years old) of patients enrolled in our study may also have resulted in the lower prevalence of AF in our study population. Theoretically, patients without previous diagnosis of stable CAD and/or without history of revascularization may be younger and have fewer AF risk factors. Although ethnicity may play a role for differences in the prevalence of AF, no evidence has been reported showing different rates of AF between Turkey and the rest of the World<sup>17,18</sup>. However, acute coronary syndrome registries conducted in Turkey report younger average ages in patients admitted with acute MI than in European countries and the United States<sup>19-22</sup>. We believe that the younger age pattern may have an effect on lower AF prevalence in our study than that of other global registries<sup>2,7</sup>.

Our study also found that non-ST-elevation myocardial infarction (NSTEMI) presentation was higher in the AF population than in patients without AF, with approximately 70% of AF patients presenting with NSTEMI. Age is a common risk factor of both AF and NSTEMI. The current literature shows a positive correlation between increasing age and the rate of NSTEMI in the MI population and a higher prevalence of AF in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS)<sup>23</sup>. On the other hand, AF with fast ventricular response can precipitate Type 2 MI that commonly presents with ST segment changes rather than elevation on admission ECG<sup>24</sup>. However, while this study did not find any differences in the prevalence of MINOCA between the AF and non-AF groups, possible type II error cannot be ignored.

Advanced age, female gender, lower LV ejection fraction (LVEF), higher Killip class, obesity, presence of multiple comorbidities, and hemodynamic instability are associated with AF<sup>2,25-27</sup>. Similar to previous studies, patients in the AF group were older than in the non-

**Table 3: Preferred treatment strategies for coronary artery disease (p=0.884)**

	AF patients(n=51)	non-AF patients(n=1575)
Percutaneous coronary intervention (PCI), n (%)	38 (74.5%)	1244 (79.0%)
Coronary artery bypass grafting (CABG), n (%)	5 (9.8%)	166 (10.6%)
Medical management, n (%)	8 (15.7%)	158 (10.0%)
Other options, n (%)	0 (0.0%)	7 (0.4%)

AF group and the proportion of women to men in the AF group was higher than that in the non-AF group. Previous registries revealed that with advanced age, gender difference in MI patients lessens and the female/male ratio increases<sup>28</sup>. AF patients were an average of twelve years older than non-AF patients in our study, which may explain the gender difference between the AF and non-AF groups. Additionally, smoking is more common in men than in women in the Turkish population<sup>29</sup>. The authors believe that the observed difference in smoking between the groups may be due to the female dominance in the AF group. Hypertension is an essential predictor of AF development<sup>30</sup> and higher hypertension prevalence in the AF group can play a role in the development of AF in advanced age (64.7% vs. 48.5%, p=0.023). In addition, we should pay attention to type I statistical error in evaluations of differences of gender, smoking, and prevalence of hypertension in this context. Lower LVEF in the AF group (45.0% [30.0-50.0] vs. 50.0% [35.0-55.0], p=0.008) can be explained by the higher burden of comorbidities such as advanced age and hypertension in AF patients<sup>31</sup>. Loss of atrial kick and possible tachycardiomyopathy are other factors that may result in lower EF and have been found to be responsible for worse hemodynamic status and increased mortality<sup>32</sup>. Accordingly, the ratio of Killip class 3 and 4 patients at admission was higher in the AF group in our study.

An interesting finding in our study was the relatively low percentage of patients who were initially treated by the thrombolytic therapy. ST-elevation myocardial infarction (STEMI) patients made up nearly half of the study population (46.0%) but only 3.0% of all patients received thrombolytic treatment before coronary angiography. Even in the AF group, while 31.3% of patients presented with STEMI, none received thrombolytic therapy. It is possible that the lower preference for thrombolytic therapy as an initial reperfusion choice may be related to the well-organized ambulance system and sufficient number of invasive cardiology centers which are capable of performing 7/24 primary PCI around the country.

Oral P2Y<sub>12</sub> inhibitor loading was common in both AF and non-AF patients. Although the AF group was found to have a higher oral P2Y<sub>12</sub> inhibitor loading rate (96.0% vs. 91.8%, p=0.027) than the non-AF group, this can be an incidental finding and accepted as an example of type I statistical error. The study also found the use of oral P2Y<sub>12</sub> inhibitors other than clopidogrel to be relatively common in the AF group, with approximately one third of patients in the AF group loaded with an oral P2Y<sub>12</sub> inhibitor other than clopidogrel. We believe that the relatively common use of more potent P2Y<sub>12</sub> inhibitors in AF population was due to the lower percentage of AF patients who had been already taken OAC therapy. It can be argued that with common OAC usage, potent P2Y<sub>12</sub> inhibitor loading ratios would be lower.

Ischemic stroke is a devastating complication of AF and MI patients with AF carry a significant risk of stroke. Previously, it has been reported that dual/triple therapy by adding an OAC decreases the risk of stroke<sup>33,34</sup>. Despite this stroke risk, most AF patients admitted with MI were discharged without any OAC therapy<sup>3</sup>. Many trials have focused on finding the sweet spot between stroke, stent thrombosis, and major bleeding risk and compared triple and dual therapy strategies with different duration and different regimens. Almost all of reported greater safety with dual therapy with OAC plus clopidogrel than triple therapy<sup>35-41</sup>. Current guidelines advise personalized management of these patients according to bleeding and thrombosis risk<sup>42,43</sup>. It is also important to emphasize the low percentage of oral anticoagulant usage in patients with AF before emergency admission.

Underdiagnosed/overlooked AF, particularly in asymptomatic patients, undertreatment, and compliance issues with OAC therapy may be the main reasons for the lower percentage of OAC use in the study population. These results show the importance of successful and timely diagnosis of AF, patient education on OAC therapy, and transparent performance metrics and guideline adaptation for health providers.

### Limitations

The study had several limitations discussed below. Regarding the cross-sectional design of the study, it was not possible to obtain short and long-term prognostic metrics of the patient population. Due to the relatively small sample size of the AF population, possible type II statistical errors may have affected the comparative data. Some demographic and clinical characteristics of the study population may be specific to the Turkish population and thus not reflect a global perspective. MI was defined in line with the Third Universal Definition of Myocardial Infarction. However, the current Fourth Universal Definition of Myocardial Infarction was published after the starting date of study and protocol revisions were not made due to possible risks of harmonization between pre- and post-revision data. AF diagnosis was based on a<sup>12</sup> lead ECG performed at admission, meaning that incident AF could not be captured and differentiated from existing chronic patterns. For this reason, the organizing committee required the completion of a form from the investigators in case with suspicion of incident AF. Similarly, we did not receive any data about the patterns of AF (ie first diagnosed, paroxysmal, persistent, etc). A higher rate of first diagnosed AF patterns may explain the dramatic percentages of OAC use in the study population.

### Conclusions

In conclusion, the study reports a lower percentage of AF prevalence in the de novo MI population than previous studies of enrolled unselected MI and ACS cohorts. It also demonstrated the underuse of OAC in AF patients, emphasizing the vital role of opportunistic diagnostic strategies, patient education, and implementations for guideline adaptation.

### References

1. Kalarus Zbigniew, SvendsenJesper Hastrup, CapodannoDavide, DanGheorghe-Andrei, De MariaElia, GorenekBulent, Jędrzejczyk-PatejEwa, MazurekMichał, PodoleckiTomasz, SticherlingChristian, Tfelt-HansenJacob, TraykovVassil,

- LipGregory Y H, FauchierLaurent, BorianiGiuseppe, MansouratiJacques, Blomström-LundqvistCarina, MairesseGeorges H, RubboliAndrea, DenekeThomas, DagresNikolaos, SteenTorkel, AhrensIngo, KunadianVijay, BertiSergio. Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). *Europace*. 2019;21 (10):1603–1604.
2. Schmitt Joern, DurayGabor, GershBernard J, HohnloserStefan H. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. *Eur Heart J*. 2009;30 (9):1038–45.
  3. Dai Yan, YangJingang, GaoZhan, XuHaiyan, SunYi, WuYuan, GaoXiaojin, LiWei, WangYang, GaoRunlin, YangYuejin. Atrial fibrillation in patients hospitalized with acute myocardial infarction: analysis of the china acute myocardial infarction (CAMI) registry. *BMC Cardiovasc Disord*. 2017;17 (1).
  4. Ibanez Borja, JamesStefan, AgewallStefan, AntunesManuel J, Bucciarelli-DucciChiara, BuenoHéctor, CaforioAlida L P, CreaFilippo, GoudevenosJohn A, HalvorsenSigrun, HindricksGerhard, KastratiAdnan, LenzenMattie J, PrescottEva, RoffiMarco, ValgimigliMarco, VarenhorstChristoph, VranckxPascal, WidimskyPetr. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2018;39 (2):119–177.
  5. Sonu Gupta, RupakDesai, BishoyHanna, AbhishekDeshmukh, GautamKumar, RajeshSachdeva, AdamE Berman. The Impact of Atrial Fibrillation on In-Hospital Outcomes in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Coronary Revascularization with Percutaneous Ventricular Assist Device Support. *J Atr Fibrillation*. 2020;12 (5).
  6. Nagai Mizuyoshi, ItohTomonori, IshidaMasaru, FusazakiTetsuya, KomatsuTakashi, NakamuraMotoyuki, MorinoYoshihiro. New-onset atrial fibrillation in patients with acute coronary syndrome may be associated with worse prognosis and future heart failure. *J Arrhythm*. 2019;35 (2):182–189.
  7. Køber Lars, SwedbergKarl, McMurrayJohn J V, PfefferMarc A, VelazquezEric J, DiazRafael, MaggioniAldo P, MareevViatcheslav, OpolskiGrzegorz, Van de WerfFrans, ZannadFaiez, ErtlGeorg, SolomonScott D, ZelenkofskeSteven, RouleauJean-Lucien, LeimbergerJeffrey D, CaliffRobert M. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. *Eur J Heart Fail*. 2006;8 (6):591–8.
  8. Türk Uğur Önsel, ZoghiMehdi, AlioğluEmin, ErgeneOktay. Rationale and design of the Myocardial Infarction with Non-obstructive Coronary Arteries in Turkish Population (MINOCA-TR) study. *Türk Kardiyol Dern Ars*. 2019;47 (8):662–668.
  9. Kilic Salih, AydınGökhan, ÇonerAli, DoğanYasemin, Arican ÖzlükÖzlem, ÇelikYunus, UnganIsmail, TascanovMustafa Begenc, DüzRamazan, PolatVeli, ÖzkanHakan, ÖzyaşarMehmet, TülüceKamil, KurtDevrim, ÇetinNurullah, GülMurat, İnciSinan, Yılmaz CoskunFatma, ArıHasan, ZoghiMegdi, ErgeneAsim Oktay, TürkUğur Önsel. Prevalence and clinical profile of patients with myocardial infarction with non-obstructive coronary arteries in Turkey (MINOCA-TR): A national multi-center, observational study. *Anatol J Cardiol*. 2020;23 (3):176–182.
  10. McManus David D, HuangWei, DomakondaKunal V, WardJeanine, SaczynskijJane S, GoreJoel M, GoldbergRobert J. Trends in atrial fibrillation in patients hospitalized with an acute coronary syndrome. *Am J Med*. 2012;125 (11):1076–84.
  11. Galvão Braga Carlos, RamosVitor, VieiraCatarina, MartinsJuliana, RibeiroSilvia, GasparAntônio, SalgadoAlberto, AzevedoPedro, Alvares PereiraMiguel, MagalhãesSônia, CorreiaAdelino. New-onset atrial fibrillation during acute coronary syndromes: predictors and prognosis. *Rev Port Cardiol*. 2014;33 (5):281–7.
  12. Rene A Garvey, GénereuxPhilippe, EzekowitzMichael, KirtaneAjay J, XuKe, MehranRoxana, BrenerSorin J, StoneGregg W. Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). *Am J Cardiol*. 2014;113 (2):236–42.
  13. Yasuda Satoshi, KaikitaKoichi, AkaoMasaharu, AkoJunya, MatobaTetsuya, NakamuraMasato, MiyauchiKatsumi, HagiwaraNobuhisa, KimuraKazuo, HirayamaAtsushi, MatsuiKunihiko, OgawaHisao. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. *N Engl J Med*. 2019;381 (12):1103–1113.
  14. Banach Maciej, RyszJacek, DrozdJarosław Aw, OkonskiPiotr, MisztalMalgorzata, BarylskiMarcin, IrmanskiRobert, ZaslonkaJanusz. Risk factors of atrial fibrillation following coronary artery bypass grafting: a preliminary report. *Circ J*. 2006;70 (4):438–41.
  15. Rathore S S, BergerA K, WeinfurtK P, SchulmanK A, OetgenW J, GershB J, SolomonA J. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. *Circulation*. 2000;101 (9):969–74. [ PubMed ]
  16. Fang Margaret C, ChenJane, RichMichael W. Atrial fibrillation in the elderly. *Am J Med*. 2007;120 (6):481–7.
  17. Yavuz Bünyamin, AtaNaım, OtoEmre, Katircioglu-ÖztürkDeniz, AytemirKudret, EvranosBanu, KoselerliRasim, ErtugayEmre, BurkanAbdulkadir, ErtugayEmrah, GaleChrist P, CammA John, OtoAli. Demographics, treatment and outcomes of atrial fibrillation in a developing country: the population-based Turkish Atrial Fibrillation (TRAF) cohort. *Europace*. 2017;19 (5):734–740.
  18. Başaran Özcan, BetonOsman, DoğanVolkan, TekinalpMehmet, AykanAhmet Çağrı, KalaycıoğluEzgi, Bolatİsmail, TaşarOnur, ŞafakÖzgen, KalçıkMacit, YamanMehmet, Altunİbrahim, SoyluMustafa Özcan, KirmaCevat, BitekerMurat. ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). *Anatol J Cardiol*. 2016;16 (10):734–741.
  19. Ertaş Fatih Sinan, TokgözoğluLale. Pre- and in-hospital antithrombotic management patterns and in-hospital outcomes in patients with acute coronary syndrome: data from the Turkish arm of the EPICOR study. *Anatol J Cardiol*. 2016;16 (12):900–915.
  20. Tokgözoğlu Lale, KayaErgün Bariş, ErolCetin, ErgeneOktay. [EUROASPIRE III: a comparison between Turkey and Europe]. *Türk Kardiyol Dern Ars*. 2010;38 (3):164–72.
  21. Hanssen Michel, CottinYves, KhalifeKhalife, HammerLaure, GoldsteinPatrick, PuymiratEtienne, MulakGeneviève, DrouetElodie, PaceBenoit, SchultzEric, BatailleVincent, FerrièresJean, SimonTabassome, DanchinNicolas. French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. *FAST-MI 2010*. *Heart*. 2012;98 (9):699–705.
  22. Awad Hamza H, ZubaidMohammad, Alsheikh-AliAlawi A, Al SuwaidiJassim, AndersonFrederick A, GoreJoel M, GoldbergRobert J. Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events. *Am J Cardiol*. 2011;108 (9):1252–8.
  23. Mohamed Mohamed Osama, KirchhoffPaulus, VidovichMladen, SavageMichael, RashidMuhammad, KwokChun Shing, ThomasMark, El OmarOmar, Al AyoubiFakhr, FischmanDavid L, MamasMamas Andreas. Effect of Concomitant Atrial Fibrillation on In-Hospital Outcomes of Non-ST-Elevation-Acute Coronary Syndrome-Related Hospitalizations in the United States. *Am J Cardiol*. 2019;124 (4):465–475.
  24. González-Pacheco Héctor, MárquezManlio F, Arias-MendozaAlexandra, Álvarez-SangabrielAmada, Eid-LidtGuering, González-HermosilloAntonio, Azar-ManzurFrancisco, Altamirano-CastilloAlfredo, Briseño-CruzJosé Luis, García-MartínezAdolfo, Mendoza-GarcíaSalvador, Martínez-SánchezCarlos. Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation. *J Cardiol*. 2015;66 (2):148–54.

25. Mehta Rajendra H, Dabbous Omar H, Granger Christopher B, Kuznetsova Polina, Kline-Rogers Eva M, Anderson Frederick A, Fox Keith A A, Gore Joel M, Goldberg Robert J, Eagle Kim A. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. *Am J Cardiol.* 2003;92 (9):1031–6.
26. Vermond Rob A, Geelhoed Bastiaan, Verweij Niek, Tieleman Robert G, Van der Harst Pim, Hillege Hans L, Van Gilst Wiek H, Van Gelder Isabelle C, Rienstra Michiel. Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based Study From the Netherlands. *J Am Coll Cardiol.* 2015;66 (9):1000–7.
27. Storz Maximilian Andreas, Helle Paul. Atrial fibrillation risk factor management with a plant-based diet: A review. *J Arrhythm.* 2019;35 (6):781–788.
28. Mehta Laxmi S, Beckie Theresa M, De Von Holli A, Grines Cindy L, Krumholz Harlan M, Johnson Michelle N, Lindley Kathryn J, Vaccarino Viola, Wang Tracy Y, Watson Karol E, Wenger Nanette K. Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association. *Circulation.* 2016;133 (9):916–47.
29. Kilic Dilek, Ozturk Selcen. Gender differences in cigarette consumption in Turkey: evidence from the Global Adult Tobacco Survey. *Health Policy.* 2014;114 (2-3):207–14.
30. Kallistratos M S, Poulimenos L E, Manolis A J. Atrial fibrillation and arterial hypertension. *Pharmacol Res.* 2018;128 ( ):322–326.
31. Batul Syeda Atiqa, Gopinathannair Rakesh. Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times. *Korean Circ J.* 2017;47 (5):644–662.
32. Namana V, Gupta S S, Sabharwal N, Hollander G. Clinical significance of atrial kick. *QJM.* 2018;111 (8):569–570.
33. Lopes Renato D, Elliott Laine E, White Harvey D, Hochman Judith S, Van de Werf Frans, Ardissino Diego, Nielsen Torsten T, Weaver W Douglas, Widimsky Petr, Armstrong Paul W, Granger Christopher B. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. *Eur Heart J.* 2009;30 (16):2019–28.
34. Saito Yuichi, Kobayashi Yoshio. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention. *J Cardiol.* 2019;73 (1):1–6.
35. Shinohara Masaya, Wada Ryou, Yao Shintaro, Yano Kensuke, Akitsu Katsuya, Koike Hideki, Kinoshita Toshio, Yuzawa Hitomi, Suzuki Takeya, Fujino Tadashi, Ikeda Takanori. Evaluation of oral anticoagulants in atrial fibrillation patients over 80 years of age with nonsevere frailty. *J Arrhythm.* 2019;35 (6):795–803.
36. Dewilde Willem J M, Oirbans Tom, Verheugt Freek W A, Kelder Johannes C, De Smet Bart J G L, Herrman Jean-Paul, Adriaenssens Tom, Vrolix Mathias, Heestermans Antonius A C M, Vis Marije M, Tijssen Jan G P, van 't Hof Arnoud W, ten Berg Jurrien M. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet.* 2013;381 (9872):1107–15.
37. Cannon Christopher P, Bhatt Deepak L, Oldgren Jonas, Lip Gregory Y H, Ellis Stephen G, Kimura Takeshi, Maeng Michael, Merkely Bela, Zeymer Uwe, Gropper Savion, Nordaby Matias, Kleine Eva, Harper Ruth, Manassie Jenny, Januzzi James L, Ten Berg Jurrien M, Steg P Gabriel, Hohnloser Stefan H. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. *N Engl J Med.* 2017;377 (16):1513–1524.
38. Gibson C Michael, Mehran Roxana, Bode Christoph, Halperin Jonathan, Verheugt Freek W, Wildgoose Peter, Birmingham Mary, Ianus Juliana, Burton Paul, van Eickels Martin, Korjian Serge, Daaboul Yazan, Lip Gregory Y H, Cohen Marc, Husted Steen, Peterson Eric D, Fox Keith A. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. *N Engl J Med.* 2016;375 (25):2423–2434.
39. Windecker Stephan, Lopes Renato D, Massaro Tyler, Jones-Burton Charlotte, Granger Christopher B, Aronson Ronald, Heizer Gretchen, Goodman Shaun G, Darius Harald, Jones W Schuyler, Aschermann Michael, Brieger David, Cura Fernando, Engström Thomas, Fridrich Viliam, Halvorsen Sigrun, Huber Kurt, Kang Hyun-Jae, Leiva-Pons Jose L, Lewis Basil S, Malaga German, Meneveau Nicolas, Merkely Bela, Milicic Davor, Morais João, Potpara Tatjana S, Raev Dimitar, Sabaté Manel, de Waha-Thiele Suzanne, Welsh Robert C, Xavier Denis, Mehran Roxana, Alexander John H. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. *Circulation.* 2019;140 (23):1921–1932.
40. Vranckx Pascal, Valgimigli Marco, Eckardt Lars, Tijssen Jan, Lewalter Thorsten, Gargiulo Giuseppe, Batushkin Valerii, Campo Gianluca, Lysak Zoreslava, Vakaliuk Igor, Milewski Krzysztof, Laeis Petra, Reimitz Paul-Egbert, Smolnik Rüdiger, Zierhut Wolfgang, Goette Andreas. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. *Lancet.* 2019;394 (10206):1335–1343.
41. Lopes Renato D, Hong Hwanhee, Harskamp Ralf E, Bhatt Deepak L, Mehran Roxana, Cannon Christopher P, Granger Christopher B, Verheugt Freek W A, Li Jianghao, Ten Berg Jurrien M, Sarafoff Nikolaus, Vranckx Pascal, Goette Andreas, Gibson C Michael, Alexander John H. Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. *JAMA Cardiol.* 2020;5 (5):582–589.
42. January Craig T, Wann L Samuel, Calkins Hugh, Chen Lin Y, Cigarroa Joaquin E, Cleveland Joseph C, Ellinor Patrick T, Ezekowitz Michael D, Field Michael E, Furie Karen L, Heidenreich Paul A, Murray Katherine T, Shea Julie B, Tracy Cynthia M, Yancy Clyde W. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. *Circulation.* 2019;140 (2):e125–e151.
43. Steffel Jan, Verhamme Peter, Potpara Tatjana S, Albaladejo Pierre, Antz Matthias, Desteghe Lien, Haecusler Karl Georg, Oldgren Jonas, Reinecke Holger, Roldan-Schilling Vanessa, Rowell Nigel, Sinnaeve Peter, Collins Ronan, Camm A John, Heidbüchel Hein. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J.* 2018;39 (16):1330–1393.